Sarepta Therapeutics, Inc. (SRPT) Q4 2018 Earnings Results

Sarepta Therapeutics Misses on EPS — Stock Up 8.31%

Sarepta Therapeutics reported a larger-than-expected loss in EPS, which typically raises concerns among investors. However, the stock rose by 8.31%, likely driven by optimism around their ongoing projects and potential future developments. The lack of revenue data and guidance may leave some investors cautious, but the market seems to be reacting positively to the company's long-term vision.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.85	N/A	-32.91%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced this quarter but remains focused on long-term goals. They did not provide specific guidance for the future.

Management highlighted ongoing challenges in meeting financial expectations.

They emphasized their commitment to advancing their pipeline despite the current losses.

Sarepta Therapeutics Misses on EPS — Stock Up 8.31%

Key numbers

Management commentary

Sarepta Therapeutics, Inc.

More earnings this week

Sarepta Therapeutics Misses on EPS — Stock Up 8.31%

Key numbers

Management commentary